CCR5 is a seven-transmembrane GPCR involved in immune cell migration (chemotaxis) and inflammatory responses . Its ligands include chemokines such as CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), which regulate T-cell trafficking and macrophage activation . In HIV research, CCR5 serves as a primary co-receptor for viral entry, making it a therapeutic target for inhibitors like maraviroc .
Key roles:
This recombinant protein is utilized in:
Structural studies: CCR5’s transmembrane topology and ligand-binding mechanisms are analyzed using cryo-EM and X-ray crystallography . For example, the N-terminal domain and extracellular loops form critical binding interfaces for chemokines like CCL5 .
HIV inhibition assays: Compounds targeting CCR5 (e.g., AOP-RANTES, NNY-RANTES) are tested for blocking viral entry .
Cross-species virology: Non-human primate CCR5 variants, including Nasalis larvatus, help study HIV adaptation and zoonotic potential .
While human and Nasalis CCR5 share 92% sequence homology, subtle differences in extracellular loops impact ligand binding and viral tropism . For instance:
The V3 loop of HIV gp120 interacts with CCR5’s extracellular domains, and mutations here alter coreceptor specificity .
Nasalis CCR5’s conserved disulfide bonds (Cys28–Cys274) stabilize its tertiary structure, similar to human CCR5 .
Storage: Lyophilized protein remains stable at -80°C but degrades upon repeated thawing .
Activity assays: Functional validation requires reconstitution in lipid bilayers or cell membranes to preserve GPCR conformation .
Safety: Not for human therapeutic use due to potential immunogenicity .
Research priorities include: